NCT03469583View on ClinicalTrials.gov

Drug Drug Interaction Study for EYP001 With Entecavir

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

June 20, 2018

Study Completion Date

July 20, 2018

Conditions

Hepatitis B, Chronic

Interventions

DRUG

EYP001

EYP001 self administered capsules, morning, with non carbonated water

DRUG

Entecavir 1 MG

Entecavir self administered tablets, morning, with non carbonated water

Trial Locations (1)

5000

Cmax Clinical Research Pty Ltd, Adelaide

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

CPR Pharma Services Pty Ltd, Australia

INDUSTRY

lead

Enyo Pharma

INDUSTRY